4,862 Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX) Acquired by Integrated Wealth Concepts LLC

Integrated Wealth Concepts LLC purchased a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 4,862 shares of the biotechnology company’s stock, valued at approximately $308,000.

Several other institutional investors have also modified their holdings of the business. Hilltop Holdings Inc. raised its holdings in Viking Therapeutics by 45.3% in the third quarter. Hilltop Holdings Inc. now owns 9,777 shares of the biotechnology company’s stock valued at $619,000 after acquiring an additional 3,047 shares in the last quarter. Cinctive Capital Management LP lifted its position in shares of Viking Therapeutics by 81.4% during the 3rd quarter. Cinctive Capital Management LP now owns 65,080 shares of the biotechnology company’s stock worth $4,120,000 after purchasing an additional 29,204 shares during the last quarter. Erste Asset Management GmbH acquired a new position in shares of Viking Therapeutics during the third quarter worth $2,897,000. Bellevue Group AG raised its stake in Viking Therapeutics by 267.7% in the third quarter. Bellevue Group AG now owns 16,179 shares of the biotechnology company’s stock valued at $1,024,000 after buying an additional 11,779 shares in the last quarter. Finally, Braidwell LP lifted its holdings in Viking Therapeutics by 4.5% during the 3rd quarter. Braidwell LP now owns 1,156,977 shares of the biotechnology company’s stock worth $73,248,000 after buying an additional 50,072 shares during the last quarter. Institutional investors and hedge funds own 76.03% of the company’s stock.

Viking Therapeutics Stock Performance

Shares of VKTX opened at $47.87 on Friday. The stock has a market capitalization of $5.33 billion, a P/E ratio of -51.47 and a beta of 0.88. Viking Therapeutics, Inc. has a 1 year low of $17.23 and a 1 year high of $99.41. The company’s fifty day moving average is $60.03 and its two-hundred day moving average is $58.61.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings results on Wednesday, October 23rd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. During the same quarter last year, the business earned ($0.23) EPS. Sell-side analysts predict that Viking Therapeutics, Inc. will post -0.97 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on VKTX. William Blair reissued an “outperform” rating on shares of Viking Therapeutics in a research report on Wednesday, November 20th. Morgan Stanley reiterated an “overweight” rating and set a $105.00 target price on shares of Viking Therapeutics in a research report on Thursday, September 12th. B. Riley started coverage on Viking Therapeutics in a research report on Friday, November 22nd. They issued a “buy” rating and a $109.00 target price for the company. Piper Sandler began coverage on Viking Therapeutics in a research report on Monday, December 2nd. They set an “overweight” rating and a $74.00 price target on the stock. Finally, Oppenheimer reissued an “outperform” rating and issued a $138.00 price objective on shares of Viking Therapeutics in a report on Wednesday, September 25th. One equities research analyst has rated the stock with a sell rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $106.75.

Insiders Place Their Bets

In other Viking Therapeutics news, Director Sarah Kathryn Rouan sold 11,000 shares of the company’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $80.89, for a total transaction of $889,790.00. Following the transaction, the director now directly owns 9,500 shares in the company, valued at approximately $768,455. This represents a 53.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Brian Lian sold 216,130 shares of Viking Therapeutics stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $70.83, for a total transaction of $15,308,487.90. Following the sale, the chief executive officer now owns 2,304,927 shares of the company’s stock, valued at approximately $163,257,979.41. The trade was a 8.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 371,117 shares of company stock worth $27,140,009. Company insiders own 4.70% of the company’s stock.

Viking Therapeutics Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.